Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilgiç Temel, Aslı, Bassorgun, Cumhur Ibrahim, Akman-Karakaş, Ayşe, Alpsoy, Erkan, Uzun, Soner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Single Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346946/
https://www.ncbi.nlm.nih.gov/pubmed/28413387
http://dx.doi.org/10.1159/000452828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346946/
https://www.ncbi.nlm.nih.gov/pubmed/28413387
http://dx.doi.org/10.1159/000452828

Ejemplares similares